Creative Medical Technology Holdings, Inc. (CELZ): Shareholders' Equity
$7.51M
As of 2025-12-31
$8.65M
As of 2026-06-30
-22.0%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.51M | +18.5% | 2026-03-20, Balance as of period end |
| 2024-12-31 | $6.34M | -38.7% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $10.34M | -34.8% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $15.86M | +55.3% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $10.22M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | -$39.80M | n/m | 2022-03-30, Balance as of period end |
| 2019-12-31 | -$8.07M | n/m | 2021-03-17, Balance as of period end |
| 2018-12-31 | -$3.99M | n/m | 2020-04-06, Balance as of period end |
| 2017-12-31 | -$2.24M | n/m | 2019-04-01, Balance as of period end |
| 2016-12-31 | -$157.8K | n/m | 2018-03-29, Balance as of period end |
| 2015-12-31 | -$183.8K | n/m | 2016-04-14, Balance as of period end |
| 2014-12-31 | -$153.0K | n/m | 2016-04-14, Balance as of period end |
| 2013-12-31 | -$125.0K | n/m | 2015-02-27, Balance as of period end |
| 2012-12-31 | -$97.7K | n/m | 2014-03-17, Balance as of period end |
| 2011-12-31 | -$72.2K | n/m | 2012-03-26, Balance as of period end |
| 2010-12-31 | -$48.1K | n/a | 2012-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.51M | +18.5% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $5.59M | -78.2% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $13.10M | +62.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $23.52M | -26.7% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$9.78M | n/m |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$1.10M | n/m |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$514.9K | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $67.48M | -3.6% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
Compare CELZ, SNTI, ENTX, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗